Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis
Diffuse alveolar hemorrhage (DAH) is a serious complication of the small vessel vasculitis syndromes and carries a high mortality. Recombinant activated factor VII (rFVIIa) is used to treat bleeding in patients with hemophilia and antibodies to factor VIII or IX. It is increasingly being used in lif...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2014/283086 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562636475072512 |
|---|---|
| author | Dania Khoulani Bharat Rao Ammar Khanshour Philip Kuriakose Lenar Yessayan |
| author_facet | Dania Khoulani Bharat Rao Ammar Khanshour Philip Kuriakose Lenar Yessayan |
| author_sort | Dania Khoulani |
| collection | DOAJ |
| description | Diffuse alveolar hemorrhage (DAH) is a serious complication of the small vessel vasculitis syndromes and carries a high mortality. Recombinant activated factor VII (rFVIIa) is used to treat bleeding in patients with hemophilia and antibodies to factor VIII or IX. It is increasingly being used in life-threatening hemorrhage in a variety of other settings in which conventional therapy is unsuccessful. Randomized controlled trials of rFVIIa in DAH are lacking. However, several case reports have described a complete or sustained control of DAH using rFVIIa after patients failed to respond to medical treatment. There are no case reports in the literature describing the use or the failure of rFVIIa in DAH associated with cryoglobulinemic vasculitis. We here report the failure of rFVIIa to control DAH in a patient with CD5+ B-cell non-Hodgkin’s lymphoma and cryoglobulinemic vasculitis. |
| format | Article |
| id | doaj-art-c46772a269ac4584bf88b88179757193 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-c46772a269ac4584bf88b881797571932025-02-03T01:22:09ZengWileyCase Reports in Hematology2090-65602090-65792014-01-01201410.1155/2014/283086283086Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic VasculitisDania Khoulani0Bharat Rao1Ammar Khanshour2Philip Kuriakose3Lenar Yessayan4Department of Internal Medicine, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USADepartment of Internal Medicine, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USADepartment of Internal Medicine, Division of Hospital Medicine, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USADivision of Hematology and Oncology, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USADivision of Pulmonary and Critical Care Medicine, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USADiffuse alveolar hemorrhage (DAH) is a serious complication of the small vessel vasculitis syndromes and carries a high mortality. Recombinant activated factor VII (rFVIIa) is used to treat bleeding in patients with hemophilia and antibodies to factor VIII or IX. It is increasingly being used in life-threatening hemorrhage in a variety of other settings in which conventional therapy is unsuccessful. Randomized controlled trials of rFVIIa in DAH are lacking. However, several case reports have described a complete or sustained control of DAH using rFVIIa after patients failed to respond to medical treatment. There are no case reports in the literature describing the use or the failure of rFVIIa in DAH associated with cryoglobulinemic vasculitis. We here report the failure of rFVIIa to control DAH in a patient with CD5+ B-cell non-Hodgkin’s lymphoma and cryoglobulinemic vasculitis.http://dx.doi.org/10.1155/2014/283086 |
| spellingShingle | Dania Khoulani Bharat Rao Ammar Khanshour Philip Kuriakose Lenar Yessayan Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis Case Reports in Hematology |
| title | Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis |
| title_full | Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis |
| title_fullStr | Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis |
| title_full_unstemmed | Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis |
| title_short | Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis |
| title_sort | failure of recombinant activated factor vii in treatment of diffuse alveolar hemorrhage due to cryoglobulinemic vasculitis |
| url | http://dx.doi.org/10.1155/2014/283086 |
| work_keys_str_mv | AT daniakhoulani failureofrecombinantactivatedfactorviiintreatmentofdiffusealveolarhemorrhageduetocryoglobulinemicvasculitis AT bharatrao failureofrecombinantactivatedfactorviiintreatmentofdiffusealveolarhemorrhageduetocryoglobulinemicvasculitis AT ammarkhanshour failureofrecombinantactivatedfactorviiintreatmentofdiffusealveolarhemorrhageduetocryoglobulinemicvasculitis AT philipkuriakose failureofrecombinantactivatedfactorviiintreatmentofdiffusealveolarhemorrhageduetocryoglobulinemicvasculitis AT lenaryessayan failureofrecombinantactivatedfactorviiintreatmentofdiffusealveolarhemorrhageduetocryoglobulinemicvasculitis |